{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:48:06Z","timestamp":1792010886905,"version":"4.4.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Thymic epithelial tumors (TETs) are rare malignancies arising in an organ central to T cell development and immune tolerance, creating a distinctive interface between tumor biology and immunotherapy. Complete surgical resection remains the mainstay for resectable disease, whereas systemic treatment options for unresectable, recurrent, and metastatic TETs remain limited. The unique immunobiology of thymoma, particularly impaired central immune tolerance, may account for the unusual balance between antitumor activity and severe immune-related adverse events observed with immune checkpoint blockade. Recent molecular and immune profiling has begun to reveal biologically distinct TET subtypes and potential therapeutic vulnerabilities, including alterations in cell-cycle, PI3K\/AKT\/mTOR, RTK\/RAS\/MAPK, and DNA damage-response pathways, as well as epigenetic and immune regulatory mechanisms. Emerging strategies, including antibody\u2013drug conjugates and biomarker-informed targeted and immune therapies, may expand systemic treatment options for advanced disease. This review examines these developments in the context of the distinctive biology of the thymus and highlights the key unanswered questions that may shape the next generation of TET research and treatment.<\/jats:p>","DOI":"10.1007\/s10555-026-10384-5","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:02:25Z","timestamp":1791961345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Thymic epithelial tumors: what\u2019s next?"],"prefix":"10.1007","volume":"45","author":[{"given":"Li","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3940-4630","authenticated-orcid":false,"given":"Jens-C.","family":"Rueckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"issue":"2","key":"10384_CR1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jtho.2021.10.010","volume":"17","author":"A Marx","year":"2021","unstructured":"Marx, A., Chan, J. K. C., Chalabreysse, L., et al. (2021). The 2021 WHO classification of tumors of the thymus and mediastinum: What is new in thymic epithelial, germ cell, and mesenchymal tumors? Journal of Thoracic Oncology, 17(2), 200\u2013213.","journal-title":"Journal of Thoracic Oncology"},{"key":"10384_CR2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1288045","volume":"15","author":"M Perrino","year":"2024","unstructured":"Perrino, M., Voulaz, E., Balin, S., et al. (2024). Autoimmunity in thymic epithelial tumors: A not yet clarified pathologic paradigm associated with several unmet clinical needs. Frontiers in Immunology, 15, Article 1288045.","journal-title":"Frontiers in Immunology"},{"issue":"11","key":"10384_CR3","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jtho.2022.08.007","volume":"17","author":"CB Falkson","year":"2022","unstructured":"Falkson, C. B., Vella, E. T., Ellis, P. M., Maziak, D. E., Ung, Y. C., & Yu, E. (2022). Surgical, radiation, and systemic treatments of patients with thymic epithelial tumors: A clinical practice guideline. Journal of Thoracic Oncology, 17(11), 1258\u20131275.","journal-title":"Journal of Thoracic Oncology"},{"issue":"2","key":"10384_CR4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/j.semdp.2021.06.011","volume":"39","author":"J Prays","year":"2022","unstructured":"Prays, J., & Ortiz-Villal\u00f3n, C. (2022). Molecular landscape of thymic epithelial tumors. Seminars in Diagnostic Pathology, 39(2), 131\u2013136.","journal-title":"Seminars in Diagnostic Pathology"},{"issue":"7","key":"10384_CR5","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1007\/s11912-025-01680-4","volume":"27","author":"N Girard","year":"2025","unstructured":"Girard, N. (2025). Therapeutic management of metastatic thymoma and thymic carcinoma. Current Oncology Reports, 27(7), 906\u2013914.","journal-title":"Current Oncology Reports"},{"key":"10384_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezac274","author":"A Alkaaki","year":"2022","unstructured":"Alkaaki, A., Abo Al-Saud, A., Di Lena, \u00c9., et al. (2022). Factors predicting recurrence in thymic epithelial neoplasms. European Journal of Cardio-Thoracic Surgery. https:\/\/doi.org\/10.1093\/ejcts\/ezac274","journal-title":"European Journal of Cardio-Thoracic Surgery"},{"issue":"2","key":"10384_CR7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.athoracsur.2019.03.010","volume":"108","author":"BM Burt","year":"2019","unstructured":"Burt, B. M., Nguyen, D., Groth, S. S., et al. (2019). Utilization of minimally invasive thymectomy and margin-negative resection for early-stage thymoma. Annals of Thoracic Surgery, 108(2), 405\u2013411.","journal-title":"Annals of Thoracic Surgery"},{"issue":"2","key":"10384_CR8","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jtcvs.2019.11.114","volume":"160","author":"CJ Yang","year":"2020","unstructured":"Yang, C. J., Hurd, J., Shah, S. A., et al. (2020). A national analysis of open versus minimally invasive thymectomy for stage I to III thymoma. Journal of Thoracic and Cardiovascular Surgery, 160(2), 555\u201367.e15.","journal-title":"Journal of Thoracic and Cardiovascular Surgery"},{"issue":"3","key":"10384_CR9","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.athoracsur.2017.03.054","volume":"104","author":"H Agatsuma","year":"2017","unstructured":"Agatsuma, H., Yoshida, K., Yoshino, I., et al. (2017). Video-assisted thoracic surgery thymectomy versus sternotomy thymectomy in patients with thymoma. Annals of Thoracic Surgery, 104(3), 1047\u20131053.","journal-title":"Annals of Thoracic Surgery"},{"issue":"5","key":"10384_CR10","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.athoracsur.2017.05.074","volume":"104","author":"PJ Kneuertz","year":"2017","unstructured":"Kneuertz, P. J., Kamel, M. K., Stiles, B. M., et al. (2017). Robotic thymectomy is feasible for large thymomas: A propensity-matched comparison. Annals of Thoracic Surgery, 104(5), 1673\u20131678.","journal-title":"Annals of Thoracic Surgery"},{"issue":"2","key":"10384_CR11","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jtcvs.2024.08.005","volume":"169","author":"L Huang","year":"2025","unstructured":"Huang, L., Li, Z., Li, F., et al. (2025). Robotic-assisted extended thymectomy for large resectable thymoma: 21 years\u2019 experience. Journal of Thoracic and Cardiovascular Surgery, 169(2), 469\u201383.e10.","journal-title":"Journal of Thoracic and Cardiovascular Surgery"},{"key":"10384_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235574","author":"M Perrino","year":"2023","unstructured":"Perrino, M., Cordua, N., De Vincenzo, F., et al. (2023). Thymic epithelial tumor and immune system: The role of immunotherapy. Cancers. https:\/\/doi.org\/10.3390\/cancers15235574","journal-title":"Cancers"},{"issue":"6","key":"10384_CR13","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/ene.14820","volume":"28","author":"R \u00c1lvarez-Velasco","year":"2021","unstructured":"\u00c1lvarez-Velasco, R., Guti\u00e9rrez-Guti\u00e9rrez, G., Trujillo, J. C., et al. (2021). Clinical characteristics and outcomes of thymoma-associated myasthenia gravis. European Journal of Neurology, 28(6), 2083\u20132091.","journal-title":"European Journal of Neurology"},{"issue":"6","key":"10384_CR14","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.athoracsur.2020.12.010","volume":"112","author":"V Aprile","year":"2021","unstructured":"Aprile, V., Korasidis, S., Bacchin, D., et al. (2021). Thymectomy in myasthenic patients with thymoma: Killing two birds with one stone. The Annals of Thoracic Surgery, 112(6), 1782\u20131789.","journal-title":"The Annals of Thoracic Surgery"},{"issue":"4","key":"10384_CR15","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/ejcts\/ezab253","volume":"60","author":"G Romano","year":"2021","unstructured":"Romano, G., Zirafa, C. C., Ceccarelli, I., et al. (2021). Robotic thymectomy for thymoma in patients with myasthenia gravis: Neurological and oncological outcomes. European Journal of Cardio-Thoracic Surgery, 60(4), 890\u2013895.","journal-title":"European Journal of Cardio-Thoracic Surgery"},{"issue":"6","key":"10384_CR16","volume":"50","author":"PC Tsai","year":"2024","unstructured":"Tsai, P. C., Tseng, Y. C., Ting, Y. C., et al. (2024). Long-term follow-up of non-myasthenic patients with early-stage thymoma who underwent extended thymectomy or limited resection. European Journal of Surgical Oncology, 50(6), Article 108349.","journal-title":"European Journal of Surgical Oncology"},{"issue":"9","key":"10384_CR17","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1016\/j.asjsur.2023.03.063","volume":"46","author":"C Xu","year":"2023","unstructured":"Xu, C., Zhang, Q., Li, J., et al. (2023). Prognosis and surgical outcomes of the total thymectomy versus thymomectomy in non-myasthenic patients with early-stage thymoma: A systematic review and meta-analysis. Asian Journal of Surgery, 46(9), 3455\u20133463.","journal-title":"Asian Journal of Surgery"},{"issue":"7","key":"10384_CR18","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1097\/JTO.0b013e31828cb3c2","volume":"8","author":"YC Tseng","year":"2013","unstructured":"Tseng, Y. C., Hsieh, C. C., Huang, H. Y., et al. (2013). Is thymectomy necessary in nonmyasthenic patients with early thymoma? Journal of Thoracic Oncology, 8(7), 952\u2013958.","journal-title":"Journal of Thoracic Oncology"},{"issue":"2","key":"10384_CR19","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.athoracsur.2015.07.084","volume":"101","author":"K Nakagawa","year":"2016","unstructured":"Nakagawa, K., Yokoi, K., Nakajima, J., et al. (2016). Is thymomectomy alone appropriate for stage I (T1N0M0) thymoma? Results of a propensity-score analysis. Annals of Thoracic Surgery, 101(2), 520\u2013526.","journal-title":"Annals of Thoracic Surgery"},{"key":"10384_CR20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.lungcan.2016.06.021","volume":"101","author":"KS Narm","year":"2016","unstructured":"Narm, K. S., Lee, C. Y., Do, Y. W., et al. (2016). Limited thymectomy as a potential alternative treatment option for early-stage thymoma: A multi-institutional propensity-matched study. Lung Cancer, 101, 22\u201327.","journal-title":"Lung Cancer"},{"issue":"5","key":"10384_CR21","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2302892","volume":"389","author":"KA Kooshesh","year":"2023","unstructured":"Kooshesh, K. A., Foy, B. H., Sykes, D. B., Gustafsson, K., & Scadden, D. T. (2023). Health consequences of thymus removal in adults. New England Journal of Medicine, 389(5), 406\u2013417.","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10384_CR22","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ejcts\/ezab224","volume":"60","author":"F Guerrera","year":"2021","unstructured":"Guerrera, F., Falcoz, P. E., Moser, B., et al. (2021). Thymomectomy plus total thymectomy versus simple thymomectomy for early-stage thymoma without myasthenia gravis: A European Society of Thoracic Surgeons Thymic Working Group study. European Journal of Cardio-Thoracic Surgery, 60(4), 881\u2013887.","journal-title":"European Journal of Cardio-Thoracic Surgery"},{"issue":"1","key":"10384_CR23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jtho.2025.08.017","volume":"21","author":"BJ Resio","year":"2026","unstructured":"Resio, B. J., Canavan, M., Caturegli, G., Detterbeck, F., & Boffa, D. J. (2026). Mortality risk and cause of death associated with removal of the adult thymus: Analysis of the U.S. thymoma population. Journal of Thoracic Oncology, 21(1), 186\u2013194.","journal-title":"Journal of Thoracic Oncology"},{"issue":"12","key":"10384_CR24","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209482","volume":"102","author":"HJ Kaminski","year":"2024","unstructured":"Kaminski, H. J., Kusner, L. L., Cutter, G. R., et al. (2024). Does surgical removal of the thymus have deleterious consequences? Neurology, 102(12), Article e209482.","journal-title":"Neurology"},{"key":"10384_CR25","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejca.2021.11.028","volume":"162","author":"A Petat","year":"2022","unstructured":"Petat, A., Dansin, E., Calcagno, F., et al. (2022). Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network. European Journal of Cancer, 162, 118\u2013127.","journal-title":"European Journal of Cancer"},{"issue":"12","key":"10384_CR26","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.jtho.2025.08.011","volume":"20","author":"YH Bang","year":"2025","unstructured":"Bang, Y. H., Noh, J. M., Lee, B., et al. (2025). Perioperative pembrolizumab for locally advanced thymic epithelial tumors: A single-arm, phase 2 trial. Journal of Thoracic Oncology, 20(12), 1829\u20131842.","journal-title":"Journal of Thoracic Oncology"},{"issue":"2","key":"10384_CR27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.athoracsur.2018.08.055","volume":"107","author":"S Park","year":"2019","unstructured":"Park, S., Park, I. K., Kim, Y. T., et al. (2019). Comparison of neoadjuvant chemotherapy followed by surgery to upfront surgery for thymic malignancy. Annals of Thoracic Surgery, 107(2), 355\u2013362.","journal-title":"Annals of Thoracic Surgery"},{"issue":"1","key":"10384_CR28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.athoracsur.2020.07.069","volume":"112","author":"L Bertolaccini","year":"2021","unstructured":"Bertolaccini, L., Prisciandaro, E., Galetta, D., et al. (2021). Outcomes and safety analysis in superior vena cava resection for extended thymic epithelial tumors. Annals of Thoracic Surgery, 112(1), 271\u2013277.","journal-title":"Annals of Thoracic Surgery"},{"issue":"6","key":"10384_CR29","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.athoracsur.2021.05.077","volume":"113","author":"A Toker","year":"2022","unstructured":"Toker, A., Hayanga, J. W. A., Dhamija, A., et al. (2022). Superior vena cava reconstruction in Masaoka stage III and IVa thymic epithelial tumors. Annals of Thoracic Surgery, 113(6), 1882\u20131890.","journal-title":"Annals of Thoracic Surgery"},{"key":"10384_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezac021","author":"P Mendogni","year":"2022","unstructured":"Mendogni, P., Toker, A., Moser, B., et al. (2022). Surgical resection of Masaoka stage III thymic epithelial tumours with great vessels involvement: A retrospective multicentric analysis from the European Society of Thoracic Surgeons thymic database. European Journal of Cardio-Thoracic Surgery. https:\/\/doi.org\/10.1093\/ejcts\/ezac021","journal-title":"European Journal of Cardio-Thoracic Surgery"},{"key":"10384_CR31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.lungcan.2018.01.025","volume":"118","author":"E Ruffini","year":"2018","unstructured":"Ruffini, E., Filosso, P. L., Guerrera, F., Lausi, P., Lyberis, P., & Oliaro, A. (2018). Optimal surgical approach to thymic malignancies: New trends challenging old dogmas. Lung Cancer, 118, 161\u2013170.","journal-title":"Lung Cancer"},{"key":"10384_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.02.014","volume":"108","author":"JM Maury","year":"2017","unstructured":"Maury, J. M., Girard, N., Tabutin, M., et al. (2017). Intra-thoracic chemo-hyperthermia for pleural recurrence of thymoma. Lung Cancer, 108, 1\u20136.","journal-title":"Lung Cancer"},{"key":"10384_CR33","volume":"12","author":"W Qi","year":"2022","unstructured":"Qi, W., & Tian, H. (2022). The role of surgery in advanced thymic tumors: A retrospective cohort study. Frontiers in Oncology, 12, Article 1073641.","journal-title":"Frontiers in Oncology"},{"issue":"3","key":"10384_CR34","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ejcts\/ezv239","volume":"49","author":"T Hishida","year":"2016","unstructured":"Hishida, T., Nomura, S., Yano, M., et al. (2016). Long-term outcome and prognostic factors of surgically treated thymic carcinoma: Results of 306 cases from a Japanese nationwide database study. European Journal of Cardio-Thoracic Surgery, 49(3), 835\u2013841.","journal-title":"European Journal of Cardio-Thoracic Surgery"},{"key":"10384_CR35","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107214","volume":"180","author":"MG Mastromarino","year":"2023","unstructured":"Mastromarino, M. G., Bacchin, D., Aprile, V., et al. (2023). Unradical surgery for locally-advanced thymoma: Is it time to evolve perspectives? Lung Cancer, 180, Article 107214.","journal-title":"Lung Cancer"},{"issue":"1","key":"10384_CR36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jtcvs.2015.08.034","volume":"151","author":"G Leuzzi","year":"2016","unstructured":"Leuzzi, G., Rocco, G., Ruffini, E., et al. (2016). Multimodality therapy for locally advanced thymomas: A propensity score-matched cohort study from the European Society of Thoracic Surgeons Database. Journal of Thoracic and Cardiovascular Surgery, 151(1), 47-57.e1.","journal-title":"Journal of Thoracic and Cardiovascular Surgery"},{"issue":"4","key":"10384_CR37","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jtho.2020.12.023","volume":"16","author":"Y Tateishi","year":"2021","unstructured":"Tateishi, Y., Horita, N., Namkoong, H., Enomoto, T., Takeda, A., & Kaneko, T. (2021). Postoperative radiotherapy for completely resected Masaoka\/Masaoka-Koga stage II\/III thymoma improves overall survival: An updated meta-analysis of 4746 patients. Journal of Thoracic Oncology, 16(4), 677\u2013685.","journal-title":"Journal of Thoracic Oncology"},{"issue":"4","key":"10384_CR38","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jtho.2023.12.011","volume":"19","author":"A Rimner","year":"2024","unstructured":"Rimner, A., Ahmad, U., Lobaugh, S. M., et al. (2024). Postoperative radiation therapy for thymic carcinoma: An analysis of the International Thymic Malignancy Interest Group\/European Society of Thoracic Surgeons Database. Journal of Thoracic Oncology, 19(4), 626\u2013635.","journal-title":"Journal of Thoracic Oncology"},{"key":"10384_CR39","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110272","volume":"195","author":"H Lopez","year":"2024","unstructured":"Lopez, H., Botticella, A., Belkhir, F., et al. (2024). Postoperative radiotherapy results in 192 epithelial thymic tumours patients with 10 years of follow-up. Radiotherapy and Oncology, 195, Article 110272.","journal-title":"Radiotherapy and Oncology"},{"issue":"4","key":"10384_CR40","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.athoracsur.2020.06.078","volume":"111","author":"EK Tang","year":"2021","unstructured":"Tang, E. K., Chang, J. M., Chang, C. C., et al. (2021). Prognostic factor of completely resected and pathologic T3 N0 M0 thymic epithelial tumor. Annals of Thoracic Surgery, 111(4), 1164\u20131173.","journal-title":"Annals of Thoracic Surgery"},{"key":"10384_CR41","volume":"178","author":"Y Gao","year":"2023","unstructured":"Gao, Y., Fan, X., Hua, C., et al. (2023). Failure patterns for thymic carcinoma with completed resection and postoperative radiotherapy. Radiotherapy and Oncology, 178, Article 109438.","journal-title":"Radiotherapy and Oncology"},{"issue":"1","key":"10384_CR42","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","volume":"7","author":"A Rajan","year":"2019","unstructured":"Rajan, A., Heery, C. R., Thomas, A., et al. (2019). Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (avelumab) treatment in advanced thymoma. Journal for Immunotherapy of Cancer, 7(1), 269.","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"24","key":"10384_CR43","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","volume":"37","author":"J Cho","year":"2019","unstructured":"Cho, J., Kim, H. S., Ku, B. M., et al. (2019). Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: An open-label phase II trial. Journal of Clinical Oncology, 37(24), 2162\u20132170.","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10384_CR44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","volume":"19","author":"G Giaccone","year":"2018","unstructured":"Giaccone, G., Kim, C., Thompson, J., et al. (2018). Pembrolizumab in patients with thymic carcinoma: A single-arm, single-centre, phase 2 study. Lancet Oncology, 19(3), 347\u2013355.","journal-title":"Lancet Oncology"},{"key":"10384_CR45","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejca.2022.12.005","volume":"180","author":"J Remon","year":"2023","unstructured":"Remon, J., Villacampa, G., Facchinetti, F., et al. (2023). Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis. European Journal of Cancer, 180, 117\u2013124.","journal-title":"European Journal of Cancer"},{"issue":"7","key":"10384_CR46","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nri2993","volume":"11","author":"JF Miller","year":"2011","unstructured":"Miller, J. F. (2011). The golden anniversary of the thymus. Nature Reviews. Immunology, 11(7), 489\u2013495.","journal-title":"Nature Reviews. Immunology"},{"issue":"10","key":"10384_CR47","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1172\/JCI39269","volume":"119","author":"D Sauce","year":"2009","unstructured":"Sauce, D., Larsen, M., Fastenackels, S., et al. (2009). Evidence of premature immune aging in patients thymectomized during early childhood. Journal of Clinical Investigation, 119(10), 3070\u20133078.","journal-title":"Journal of Clinical Investigation"},{"issue":"5","key":"10384_CR48","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1084\/jem.116.5.773","volume":"116","author":"RA Good","year":"1962","unstructured":"Good, R. A., Dalmasso, A. P., Martinez, C., Archer, O. K., Pierce, J. C., & Papermaster, B. W. (1962). The role of the thymus in development of immunologic capacity in rabbits and mice. Journal of Experimental Medicine, 116(5), 773\u2013796.","journal-title":"Journal of Experimental Medicine"},{"issue":"9 Suppl 2","key":"10384_CR49","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1097\/JTO.0000000000000299","volume":"9","author":"B Weksler","year":"2014","unstructured":"Weksler, B., & Lu, B. (2014). Alterations of the immune system in thymic malignancies. Journal of Thoracic Oncology, 9(9 Suppl 2), S137\u2013S142.","journal-title":"Journal of Thoracic Oncology"},{"issue":"10 Suppl 4","key":"10384_CR50","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.1097\/JTO.0b013e3181f1f63f","volume":"5","author":"A Marx","year":"2010","unstructured":"Marx, A., Hohenberger, P., Hoffmann, H., et al. (2010). The autoimmune regulator AIRE in thymoma biology: Autoimmunity and beyond. Journal of Thoracic Oncology, 5(10 Suppl 4), S266\u2013S272.","journal-title":"Journal of Thoracic Oncology"},{"issue":"1","key":"10384_CR51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.imlet.2007.08.010","volume":"114","author":"GJ Offerhaus","year":"2007","unstructured":"Offerhaus, G. J., Schipper, M. E., Lazenby, A. J., et al. (2007). Graft-versus-host-like disease complicating thymoma: Lack of AIRE expression as a cause of non-hereditary autoimmunity? Immunology Letters, 114(1), 31\u201337.","journal-title":"Immunology Letters"},{"key":"10384_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-026-04311-4","author":"K Canaslan","year":"2026","unstructured":"Canaslan, K., Moeini Nia, F., Baez, M., et al. (2026). Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy. Cancer Immunology, Immunotherapy. https:\/\/doi.org\/10.1007\/s00262-026-04311-4","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"7","key":"10384_CR53","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11864-019-0661-2","volume":"20","author":"EA Lippner","year":"2019","unstructured":"Lippner, E. A., Lewis, D. B., Robinson, W. H., & Katsumoto, T. R. (2019). Paraneoplastic and therapy-related immune complications in thymic malignancies. Current Treatment Options in Oncology, 20(7), 62.","journal-title":"Current Treatment Options in Oncology"},{"issue":"9","key":"10384_CR54","volume":"2","author":"Y He","year":"2021","unstructured":"He, Y., Ramesh, A., Gusev, Y., Bhuvaneshwar, K., & Giaccone, G. (2021). Molecular predictors of response to pembrolizumab in thymic carcinoma. Cell Reports Medicine, 2(9), Article 100392.","journal-title":"Cell Reports Medicine"},{"issue":"9","key":"10384_CR55","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/14728222.2020.1790529","volume":"24","author":"R Berardi","year":"2020","unstructured":"Berardi, R., Goteri, G., Brunelli, A., et al. (2020). Prognostic relevance of programmed cell death protein 1\/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach. Expert Opinion on Therapeutic Targets, 24(9), 937\u2013943.","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"10384_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21239056","author":"V Tateo","year":"2020","unstructured":"Tateo, V., Manuzzi, L., De Giglio, A., et al. (2020). Immunobiology of thymic epithelial tumors: Implications for immunotherapy with immune checkpoint inhibitors. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms21239056","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10384_CR57","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12943-023-01772-4","volume":"22","author":"YQ Ao","year":"2023","unstructured":"Ao, Y. Q., Gao, J., Wang, S., et al. (2023). Immunotherapy of thymic epithelial tumors: Molecular understandings and clinical perspectives. Molecular Cancer, 22(1), 70.","journal-title":"Molecular Cancer"},{"issue":"8","key":"10384_CR58","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jtho.2018.04.013","volume":"13","author":"D Owen","year":"2018","unstructured":"Owen, D., Chu, B., Lehman, A. M., et al. (2018). Expression patterns, prognostic value, and intratumoral heterogeneity of PD-L1 and PD-1 in thymoma and thymic carcinoma. Journal of Thoracic Oncology, 13(8), 1204\u20131212.","journal-title":"Journal of Thoracic Oncology"},{"issue":"3","key":"10384_CR59","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","volume":"10","author":"SK Padda","year":"2015","unstructured":"Padda, S. K., Riess, J. W., Schwartz, E. J., et al. (2015). Diffuse high intensity PD-L1 staining in thymic epithelial tumors. Journal of Thoracic Oncology, 10(3), 500\u2013508.","journal-title":"Journal of Thoracic Oncology"},{"key":"10384_CR60","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2022.06.059","volume":"174","author":"W Wang","year":"2022","unstructured":"Wang, W., Lin, G., Hao, Y., et al. (2022). Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study. European Journal of Cancer, 174, 21\u201330.","journal-title":"European Journal of Cancer"},{"issue":"9","key":"10384_CR61","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.annonc.2024.06.002","volume":"35","author":"C Proto","year":"2024","unstructured":"Proto, C., Ganzinelli, M., Manglaviti, S., et al. (2024). Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671). Annals of Oncology, 35(9), 817\u2013826.","journal-title":"Annals of Oncology"},{"issue":"3","key":"10384_CR62","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1470-2045(25)00001-4","volume":"26","author":"T Shukuya","year":"2025","unstructured":"Shukuya, T., Asao, T., Goto, Y., et al. (2025). Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): A multicentre, single-arm, phase 2 trial. Lancet Oncology, 26(3), 331\u2013342.","journal-title":"Lancet Oncology"},{"issue":"9","key":"10384_CR63","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S1470-2045(25)00300-6","volume":"26","author":"J Remon","year":"2025","unstructured":"Remon, J., Bironzo, P., Girard, N., et al. (2025). Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): A single-arm, phase 2 trial. Lancet Oncology, 26(9), 1215\u20131226.","journal-title":"Lancet Oncology"},{"issue":"8","key":"10384_CR64","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jtho.2023.04.009","volume":"18","author":"C Proto","year":"2023","unstructured":"Proto, C., Manglaviti, S., Lo Russo, G., et al. (2023). STYLE (NCT03449173): A phase 2 trial of sunitinib in patients with type B3 thymoma or thymic carcinoma in second and further lines. Journal of Thoracic Oncology, 18(8), 1070\u20131081.","journal-title":"Journal of Thoracic Oncology"},{"issue":"10","key":"10384_CR65","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1470-2045(22)00542-3","volume":"23","author":"F Conforti","year":"2022","unstructured":"Conforti, F., Zucali, P. A., Pala, L., et al. (2022). Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): A single-arm, multicentre, phase 2 trial. Lancet Oncology, 23(10), 1287\u20131296.","journal-title":"Lancet Oncology"},{"key":"10384_CR66","volume":"145","author":"Z Li","year":"2026","unstructured":"Li, Z., Feiyue, Z., Luyu, H., Wenqiang, Z., Ismail, M., & Rueckert, J. C. (2026). Neoantigen-based dendritic cell vaccines in lung cancer: Overcoming immunosuppressive barriers for durable antitumor immunity. Cancer Treatment Reviews, 145, Article 103125.","journal-title":"Cancer Treatment Reviews"},{"key":"10384_CR67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103049","volume":"141","author":"D Miliziano","year":"2025","unstructured":"Miliziano, D., Sciortino, C., Manglaviti, S., et al. (2025). Angiogenesis and thymic epithelial tumors: From preclinical insights to different therapeutic lines and combination strategies. Cancer Treatment Reviews, 141, Article 103049.","journal-title":"Cancer Treatment Reviews"},{"issue":"2","key":"10384_CR68","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jtho.2022.10.008","volume":"18","author":"HA Jung","year":"2023","unstructured":"Jung, H. A., Kim, M., Kim, H. S., et al. (2023). A phase 2 study of palbociclib for recurrent or refractory advanced thymic epithelial tumors (KCSG LU17-21). Journal of Thoracic Oncology, 18(2), 223\u2013231.","journal-title":"Journal of Thoracic Oncology"},{"issue":"5","key":"10384_CR69","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/s41416-021-01658-6","volume":"126","author":"V Chen","year":"2022","unstructured":"Chen, V., Umemura, S., Han, Y., et al. (2022). Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine. British Journal of Cancer, 126(5), 754\u2013763.","journal-title":"British Journal of Cancer"},{"key":"10384_CR70","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107324","volume":"184","author":"V Yeung","year":"2023","unstructured":"Yeung, V., Zaemes, J., Yeh, J., et al. (2023). High levels of expression of Trop-2 in thymic epithelial tumors. Lung Cancer, 184, Article 107324.","journal-title":"Lung Cancer"},{"issue":"1","key":"10384_CR71","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1038\/s41467-025-60386-0","volume":"16","author":"S Wang","year":"2025","unstructured":"Wang, S., Yang, X., Jiang, J., et al. (2025). Cytoreductive surgery and hyperthermic intrathoracic chemotherapy in thymic epithelial tumors with pleural spread or recurrence: A prospective, single-arm, phase II study. Nature Communications, 16(1), 5175.","journal-title":"Nature Communications"},{"issue":"5","key":"10384_CR72","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/annonc\/mdu527","volume":"26","author":"D Serpico","year":"2015","unstructured":"Serpico, D., Trama, A., Haspinger, E. R., et al. (2015). Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors. Annals of Oncology, 26(5), 838\u2013847.","journal-title":"Annals of Oncology"},{"issue":"6","key":"10384_CR73","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","volume":"21","author":"J Sato","year":"2020","unstructured":"Sato, J., Satouchi, M., Itoh, S., et al. (2020). Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): A multicentre, phase 2 trial. Lancet Oncology, 21(6), 843\u2013850.","journal-title":"Lancet Oncology"},{"issue":"1","key":"10384_CR74","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.molmed.2021.10.008","volume":"28","author":"PG Manti","year":"2022","unstructured":"Manti, P. G., Trattaro, S., Castaldi, D., Pezzali, M., Spaggiari, L., & Testa, G. (2022). Thymic stroma and TFII-I: Towards new targeted therapies. Trends in Molecular Medicine, 28(1), 67\u201378.","journal-title":"Trends in Molecular Medicine"},{"issue":"12","key":"10384_CR75","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jtho.2022.08.008","volume":"17","author":"Y He","year":"2022","unstructured":"He, Y., Kim, I. K., Bian, J., et al. (2022). A knock-in mouse model of thymoma with the GTF2I L424H mutation. Journal of Thoracic Oncology, 17(12), 1375\u20131386.","journal-title":"Journal of Thoracic Oncology"},{"issue":"1","key":"10384_CR76","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s42003-022-04002-7","volume":"5","author":"OB Giorgetti","year":"2022","unstructured":"Giorgetti, O. B., Nusser, A., & Boehm, T. (2022). Human thymoma-associated mutation of the GTF2I transcription factor impairs thymic epithelial progenitor differentiation in mice. Communications Biology, 5(1), 1037.","journal-title":"Communications Biology"},{"key":"10384_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031554","author":"L Elm","year":"2024","unstructured":"Elm, L., & Levidou, G. (2024). The molecular landscape of thymic epithelial tumors: A comprehensive review. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms25031554","journal-title":"International Journal of Molecular Sciences"},{"issue":"5","key":"10384_CR78","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101627","volume":"8","author":"K Kurokawa","year":"2023","unstructured":"Kurokawa, K., Shukuya, T., Greenstein, R. A., et al. (2023). Genomic characterization of thymic epithelial tumors in a real-world dataset. ESMO Open, 8(5), Article 101627.","journal-title":"ESMO Open"},{"issue":"11","key":"10384_CR79","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/oncolo\/oyac115","volume":"27","author":"N Girard","year":"2022","unstructured":"Girard, N., Basse, C., Schrock, A., Ramkissoon, S., Killian, K., & Ross, J. S. (2022). Comprehensive genomic profiling of 274 thymic epithelial tumors unveils oncogenic pathways and predictive biomarkers. The Oncologist, 27(11), 919\u2013929.","journal-title":"The Oncologist"},{"key":"10384_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010166","author":"S Barachini","year":"2023","unstructured":"Barachini, S., Pardini, E., Burzi, I. S., Sardo Infirri, G., Montali, M., & Petrini, I. (2023). Molecular and functional key features and oncogenic drivers in thymic carcinomas. Cancers. https:\/\/doi.org\/10.3390\/cancers16010166","journal-title":"Cancers"},{"key":"10384_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143388","author":"A Szpechcinski","year":"2022","unstructured":"Szpechcinski, A., Szolkowska, M., Winiarski, S., Lechowicz, U., Wisniewski, P., & Knetki-Wroblewska, M. (2022). Targeted next-generation sequencing of thymic epithelial tumours revealed pathogenic variants in KIT, ERBB2, KRAS, and TP53 in 30% of thymic carcinomas. Cancers. https:\/\/doi.org\/10.3390\/cancers14143388","journal-title":"Cancers"},{"key":"10384_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16172966","author":"X Wang","year":"2024","unstructured":"Wang, X., Jin, H., Feng, X., Liang, Z., Jin, R., & Li, X. (2024). Depiction of the genetic alterations and molecular landscapes of thymic epithelial tumors: A systematic review and meta-analysis. Cancers. https:\/\/doi.org\/10.3390\/cancers16172966","journal-title":"Cancers"},{"issue":"2","key":"10384_CR83","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","volume":"33","author":"M Radovich","year":"2018","unstructured":"Radovich, M., Pickering, C. R., Felau, I., et al. (2018). The integrated genomic landscape of thymic epithelial tumors. Cancer Cell, 33(2), 244\u201358.e10.","journal-title":"Cancer Cell"},{"issue":"4","key":"10384_CR84","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41379-019-0382-x","volume":"33","author":"M Vivero","year":"2020","unstructured":"Vivero, M., Davineni, P., Nardi, V., Chan, J. K. C., & Sholl, L. M. (2020). Metaplastic thymoma: A distinctive thymic neoplasm characterized by YAP1-MAML2 gene fusions. Modern Pathology, 33(4), 560\u2013565.","journal-title":"Modern Pathology"},{"issue":"12","key":"10384_CR85","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/j.jtho.2021.08.008","volume":"16","author":"JC Benitez","year":"2021","unstructured":"Benitez, J. C., Boucher, M., Dansin, E., et al. (2021). Central nervous system metastases in thymic epithelial tumors: A brief report of real-world insight from RYTHMIC. Journal of Thoracic Oncology, 16(12), 2144\u20132149.","journal-title":"Journal of Thoracic Oncology"},{"key":"10384_CR86","volume":"7","author":"F Ardeshir-Larijani","year":"2023","unstructured":"Ardeshir-Larijani, F., Schneider, B. P., Althouse, S. K., et al. (2023). Clinicogenomic landscape of metastatic thymic epithelial tumors. JCO Precision Oncology, 7, Article e2200465.","journal-title":"JCO Precision Oncology"},{"issue":"8","key":"10384_CR87","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.jtho.2016.04.013","volume":"11","author":"AT Alberobello","year":"2016","unstructured":"Alberobello, A. T., Wang, Y., Beerkens, F. J., et al. (2016). PI3K as a potential therapeutic target in thymic epithelial tumors. Journal of Thoracic Oncology, 11(8), 1345\u20131356.","journal-title":"Journal of Thoracic Oncology"},{"key":"10384_CR88","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.lungcan.2016.12.005","volume":"104","author":"M Tiseo","year":"2017","unstructured":"Tiseo, M., Damato, A., Longo, L., et al. (2017). Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs). Lung Cancer, 104, 24\u201330.","journal-title":"Lung Cancer"},{"key":"10384_CR89","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.critrevonc.2016.01.012","volume":"99","author":"M Scorsetti","year":"2016","unstructured":"Scorsetti, M., Leo, F., Trama, A., et al. (2016). Thymoma and thymic carcinomas. Critical Reviews in Oncology\/Hematology, 99, 332\u2013350.","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"4","key":"10384_CR90","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1634\/theoncologist.2019-0393","volume":"25","author":"DR Principe","year":"2020","unstructured":"Principe, D. R., Kamath, S. D., Munshi, H. G., & Mohindra, N. A. (2020). Metastatic thymoma harboring a deleterious BRCA2 mutation derives durable clinical benefit from olaparib. The Oncologist, 25(4), 301\u2013305.","journal-title":"The Oncologist"},{"issue":"8","key":"10384_CR91","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/ng.3016","volume":"46","author":"I Petrini","year":"2014","unstructured":"Petrini, I., Meltzer, P. S., Kim, I. K., et al. (2014). A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nature Genetics, 46(8), 844\u2013849.","journal-title":"Nature Genetics"},{"issue":"1","key":"10384_CR92","first-page":"315","volume":"56","author":"R Kishibuchi","year":"2020","unstructured":"Kishibuchi, R., Kondo, K., Soejima, S., et al. (2020). DNA methylation of GHSR, GNG4, HOXD9 and SALL3 is a common epigenetic alteration in thymic carcinoma. International Journal of Oncology, 56(1), 315\u2013326.","journal-title":"International Journal of Oncology"},{"issue":"22","key":"10384_CR93","first-page":"2712","volume":"136","author":"S Wang","year":"2023","unstructured":"Wang, S., Gu, Z., Zhu, L., et al. (2023). Genetic insights into thymic carcinomas and thymic neuroendocrine neoplasms denote prognosis signatures and pathways. Chinese Medical Journal (English Edition), 136(22), 2712\u20132721.","journal-title":"Chinese Medical Journal (English Edition)"},{"issue":"3","key":"10384_CR94","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/path.6346","volume":"264","author":"M Latiri","year":"2024","unstructured":"Latiri, M., Belhocine, M., Smith, C., et al. (2024). DNA methylation as a new tool for the differential diagnosis between T-LBL and lymphocyte-rich thymoma. The Journal of Pathology, 264(3), 284\u2013292.","journal-title":"The Journal of Pathology"},{"key":"10384_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23074045","author":"I Psilopatis","year":"2022","unstructured":"Psilopatis, I., Pergaris, A., Vrettou, K., Theocharis, S., & Troungos, C. (2022). Thymic epithelial neoplasms: Focusing on the epigenetic alterations. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms23074045","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10384_CR96","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12943-017-0655-2","volume":"16","author":"T Bellissimo","year":"2017","unstructured":"Bellissimo, T., Ganci, F., Gallo, E., et al. (2017). Thymic epithelial tumors phenotype relies on miR-145-5p epigenetic regulation. Molecular Cancer, 16(1), 88.","journal-title":"Molecular Cancer"},{"key":"10384_CR97","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1465775","volume":"15","author":"PD Barone","year":"2024","unstructured":"Barone, P. D., & Zhang, C. (2024). Neuroendocrine neoplasms of the thymus. Frontiers in Immunology, 15, Article 1465775.","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"10384_CR98","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00428-024-03904-7","volume":"486","author":"D Suster","year":"2025","unstructured":"Suster, D., Chacko, D., VanderLaan, P., Mino-Kenudson, M., & Hung, Y. P. (2025). Insulinoma-associated protein-1 (INSM-1) is a useful diagnostic marker for the evaluation of primary thymic neuroendocrine neoplasms: An immunohistochemical study of 27 cases. Virchows Archiv, 486(4), 721\u2013727.","journal-title":"Virchows Archiv"},{"issue":"11","key":"10384_CR99","doi-asserted-by":"crossref","first-page":"L15","DOI":"10.1530\/ERC-21-0226","volume":"28","author":"A Mandl","year":"2021","unstructured":"Mandl, A., Welch, J. M., Kapoor, G., et al. (2021). Two distinct classes of thymic tumors in patients with MEN1 show LOH at the MEN1 locus. Endocrine-Related Cancer, 28(11), L15\u2013L19.","journal-title":"Endocrine-Related Cancer"},{"issue":"9","key":"10384_CR100","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.jtho.2025.04.013","volume":"20","author":"S Fodil-Cherif","year":"2025","unstructured":"Fodil-Cherif, S., Hadoux, J., Mercier, O., et al. (2025). Characterization, prognosis, and treatment of patients with locally advanced or metastatic thymic neuroendocrine tumor: A retrospective study of the French GTE, ENDOCAN RENATEN, and RYTHMIC networks. Journal of Thoracic Oncology, 20(9), 1315\u20131327.","journal-title":"Journal of Thoracic Oncology"},{"issue":"4","key":"10384_CR101","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s11154-021-09660-2","volume":"22","author":"F Guerrero-P\u00e9rez","year":"2021","unstructured":"Guerrero-P\u00e9rez, F., Peir\u00f3, I., Marengo, A. P., et al. (2021). Ectopic Cushing\u2019s syndrome due to thymic neuroendocrine tumours: A systematic review. Reviews in Endocrine & Metabolic Disorders, 22(4), 1041\u20131056.","journal-title":"Reviews in Endocrine & Metabolic Disorders"},{"key":"10384_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082370","author":"N Ose","year":"2023","unstructured":"Ose, N., Funaki, S., Kanou, T., et al. (2023). Significance of the surgical treatment with lymph node dissection for neuroendocrine tumors of thymus. Cancers. https:\/\/doi.org\/10.3390\/cancers15082370","journal-title":"Cancers"},{"issue":"15","key":"10384_CR103","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1002\/cam4.6245","volume":"12","author":"Y Guan","year":"2023","unstructured":"Guan, Y., Yao, Q., Hao, Y., et al. (2023). The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis. Cancer Medicine, 12(15), 16011\u201316018.","journal-title":"Cancer Medicine"},{"key":"10384_CR104","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108554","volume":"204","author":"V Pavese","year":"2025","unstructured":"Pavese, V., Carf\u00ec, F. M., Capelletto, E., et al. (2025). Therapeutic management of patients with advanced thymic malignancies: A review for clinicians. Lung Cancer, 204, Article 108554.","journal-title":"Lung Cancer"},{"issue":"2","key":"10384_CR105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtocrr.2025.100935","volume":"7","author":"E Pietroluongo","year":"2026","unstructured":"Pietroluongo, E., Bestvina, C. M., Brattin, R., et al. (2026). Thymic neuroendocrine tumors: Evolving insights and innovative approaches. JTO Clinical and Research Reports, 7(2), Article 100935.","journal-title":"JTO Clinical and Research Reports"},{"issue":"9","key":"10384_CR106","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/14656566.2026.2685837","volume":"27","author":"A Laffi","year":"2026","unstructured":"Laffi, A., Catania, C., De Pas, M., et al. (2026). Targeted therapies in thoracic neuroendocrine tumors: Challenges and failures of tyrosine kinase inhibition in lung and thymic carcinoids. Expert Opinion on Pharmacotherapy, 27(9), 747\u2013755.","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"4","key":"10384_CR107","doi-asserted-by":"crossref","DOI":"10.1111\/jne.70174","volume":"38","author":"E Baudin","year":"2026","unstructured":"Baudin, E., Durand, A., Buikhuisen, W., et al. (2026). European Society of Neuroendocrine Tumors (ENETS) 2025 guidance paper for lung and thymic carcinoids. Journal of Neuroendocrinology, 38(4), Article e70174.","journal-title":"Journal of Neuroendocrinology"},{"issue":"1","key":"10384_CR108","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1186\/s12885-025-13941-3","volume":"25","author":"J Capdevila","year":"2025","unstructured":"Capdevila, J., Pubul, V., Anido, U., et al. (2025). A randomized clinical trial evaluating the impact on survival and quality of life of (177)Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: The LEVEL study (GETNE T-2217). BMC Cancer, 25(1), 613.","journal-title":"BMC Cancer"},{"key":"10384_CR109","volume":"12","author":"M Liu","year":"2022","unstructured":"Liu, M., Hu, W., Zhang, Y., et al. (2022). Clinical implications of immune checkpoint markers and immune infiltrates in patients with thymic neuroendocrine neoplasms. Frontiers in Oncology, 12, Article 917743.","journal-title":"Frontiers in Oncology"},{"issue":"6","key":"10384_CR110","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105301","volume":"10","author":"K Takagi","year":"2025","unstructured":"Takagi, K., Saito, G., Tanaka, H., et al. (2025). Lenvatinib for patients with previously treated advanced thymic carcinoma in real-world settings. ESMO Open, 10(6), Article 105301.","journal-title":"ESMO Open"},{"issue":"3","key":"10384_CR111","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101576","volume":"8","author":"N Girard","year":"2023","unstructured":"Girard, N., Ponce Aix, S., Cedres, S., et al. (2023). Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial. ESMO Open, 8(3), Article 101576.","journal-title":"ESMO Open"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10384-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10384-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10384-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:13:14Z","timestamp":1792008794000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10384-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":111,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10384"],"URL":"https:\/\/doi.org\/10.1007\/s10555-026-10384-5","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"20 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"75"}}